Intellectual Developmental Disorder, X-Linked, Syndromic 37 (MRXS37): A Comprehensive Disease Characteristics Report

Summary

Intellectual Developmental Disorder, X-Linked, Syndromic 37 (MRXS37; OMIM #301118; MONDO:0958322) is an ultra-rare, recently delineated X-linked neurodevelopmental syndrome caused by germline pathogenic variants in the **ZFX gene** on chromosome Xp22.11. ZFX encodes a C2H2 zinc-finger transcription factor that escapes X-chromosome inactivation and functions as a general (housekeeping) transcriptional regulator of stem-cell self-renewal, binding GC-rich CpG-island promoters. The disorder was first characterized as a distinct clinical entity by Shepherdson and colleagues in 2024 (PMID: 38325380), who described 18 individuals (14 males, 4 females) from 16 unrelated families identified through exome or genome sequencing.

The clinical phenotype centers on **global developmental delay and intellectual disability** (ranging from borderline to moderate), **behavioral abnormalities** (autism spectrum disorder, ADHD, sleep difficulties), **hypotonia**, and a **recurrent, recognizable facial gestalt** present in every affected individual—characterized by thickening and medial broadening of the eyebrows, variations in facial shape, external eye abnormalities, a smooth and/or long philtrum, and ear abnormalities. A notable subset of families carrying missense variants also displayed **hyperparathyroidism** and an enrichment of diverse tumor types, connecting the germline disorder to ZFX's established oncogenic role in somatic cancers. Males are more severely affected than heterozygous females, consistent with X-linked inheritance modulated by skewed X-inactivation.

Mechanistically, MRXS37 arises from two variant classes: **truncating variants** (7 of 11) that likely act through loss of function (nonsense-mediated decay or removal of the DNA-binding zinc fingers), and **missense variants** (4 of 11) clustering in the penultimate/ultimate C-terminal zinc fingers responsible for DNA-binding specificity, which perturb transcriptional

activity of downstream target genes. The disorder is non-progressive (static encephalopathy), generally non-life-limiting, and managed supportively; no disease-modifying therapy exists. Because only a single cohort has been reported to date, this report reflects an evidence base derived almost entirely from one landmark study supplemented by ZFX functional biology literature.

Section 1: Disease Information

Overview. MRXS37 is a syndromic form of X-linked intellectual developmental disorder. "Syndromic" indicates that cognitive impairment is accompanied by additional recognizable features—here, a characteristic facial gestalt, behavioral abnormalities, hypotonia, congenital anomalies, and in some individuals endocrine/tumor manifestations. It belongs to the large family of X-linked intellectual disability (XLID) disorders but is distinguished by its causal gene (ZFX) and its recurrent craniofacial signature.

Key identifiers:

Resource	Identifier
OMIM (disease)	#301118
OMIM (gene, ZFX)	*314980
MONDO	MONDO:0958322
MedGen	C5935567
Gene (HGNC)	HGNC:12869 (ZFX)
NCBI Gene	7543
UniProt	P17010
Cytogenetic location	Xp22.11

Synonyms / alternative names: MRXS37; ZFX-related neurodevelopmental disorder; ZFX-associated X-linked neurodevelopmental disorder with recurrent facial gestalt. The gene ZFX carries the synonym ZNF926.

Data source type. The information is derived from **aggregated, individual-patient clinical and molecular characterization** compiled into a disease-level description—specifically deep phenotyping and genomic sequencing of 18 individuals across 16 families, not from EHR-scale population data or registries (which do not yet exist for this ultra-rare condition).

Section 2: Etiology

Disease causal factors. MRXS37 is a **monogenic genetic disorder** caused by germline variants in ZFX. There is no environmental, infectious, or acquired etiology. As stated by Shepherdson et al.: *"ZFX on Xp22.11 encodes a transcription factor that has been linked to diverse processes including oncogenesis and development, but germline variants have not been characterized in association with disease"* (PMID: 38325380).

Genetic risk factors. The causal variants are germline ZFX variants (11 identified: 4 missense, 7 truncating). All were **absent from population databases** (gnomAD, RGC-ME, All of Us), consistent with high pathogenicity. In this cohort, 10 variants were de novo and 8 were maternally inherited from mildly affected or unaffected mothers who showed skewed X-inactivation—the mother's normal X preferentially active, protecting her while transmitting the variant.

Environmental risk factors. None identified. **Sex is the principal non-genetic modifier**: males (hemizygous) are more severely affected than heterozygous females, in whom X-inactivation patterns modulate expression.

Protective factors. The only established protective mechanism is **favorably skewed X-chromosome inactivation** in carrier females, which preferentially silences the mutant allele and attenuates or abolishes phenotypic expression. No dietary, lifestyle, or pharmacologic protective factors are known.

Gene–environment interactions. No gene–environment interactions have been characterized; the disorder is essentially fully genetically determined with severity modulated by sex and X-inactivation.

Section 3: Phenotypes

All phenotype frequencies below derive from the 18-individual founding cohort (PMID: 38325380). Because the cohort is small, frequencies should be interpreted as qualitative.

Phenotype	Type	Frequency	HPO term (suggested)
Global developmental delay	Clinical sign / neurodevelopmental	Core feature	HP:0001263
Intellectual disability (borderline–moderate)	Clinical sign	Core feature	HP:0001249
Autism spectrum disorder	Behavioral	Subset	HP:0000717
Attention deficit hyperactivity disorder	Behavioral	Subset	HP:0007018
Sleep disturbance	Behavioral	Subset	HP:0002360
Hypotonia	Clinical sign	Common	HP:0001252
Thick / medially broadened eyebrows	Physical (facial)	All subjects	HP:0000574 / HP:0000280
External eye abnormalities	Physical (facial)	All subjects	HP:0000492
Smooth and/or long philtrum	Physical (facial)	All subjects	HP:0000319 / HP:0000343
Ear abnormalities	Physical (facial)	All subjects	HP:0000377
Abnormal facial shape	Physical (facial)	All subjects	HP:0001999
Hyperparathyroidism	Laboratory / endocrine	4 families (missense)	HP:0000843
Congenital anomalies (variable)	Physical	Subset	HP:0000118

Phenotype characteristics: - **Age of onset:** Congenital/neonatal to early childhood; developmental delay and facial features are apparent early. - **Severity:** Variable; intellectual disability ranges from borderline to moderate. Males more severely affected than females. -

Progression: Static/non-progressive (developmental rather than degenerative). - **The recurrent facial gestalt is the single most consistent feature—present in 100% of subjects**, per the authors: *"Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities"* (PMID: 38325380).

Quality-of-life impact. Cognitive and behavioral impairment affects education, communication, and independent living. However, functional outcomes are comparatively favorable among syndromic NDDs: many individuals attend mainstream school with support and can work under supervision. No formal QoL instrument (EQ-5D, SF-36, PROMIS) data exist for this condition.

Section 4: Genetic / Molecular Information

Causal gene. ZFX (Zinc Finger protein, X-linked), OMIM *314980, HGNC:12869, NCBI Gene 7543, UniProt P17010, located at Xp22.11. Reference transcript: NM_003410.4**.

Protein architecture. ZFX comprises an **N-terminal acidic transcriptional activation domain (~360 aa)**, a nuclear localization signal, and a **C-terminal cluster of 13 C2H2 zinc fingers**; the last three zinc fingers are necessary and sufficient for promoter recruitment.

Pathogenic variant spectrum (from Shepherdson et al. 2024): *"Four missense variants were identified in 11 subjects, with seven truncation variants in the remaining individuals"* (PMID: 38325380).

Variant class	Count	Representative variants (NM_003410.4)	Mechanism
Missense (DNA-binding domain)	4 variants / 11 subjects	c.2312C>T p.(Thr771Met) — 3 patients (RCV003991065); c.2321A>G p.(Tyr774Cys) (RCV003991066); recurrent p.(Arg786Gln) — 2 patients	Altered transcriptional activity (gain or loss); clustering in penultimate/ ultimate C-terminal zinc fingers
Truncating	7 variants	c.1319dup p.(Leu440Phefs*21) (RCV003991068); p.(Met666Valfs*2) (VCV003367188, Pathogenic); c.115_116del (2-bp)	Loss of function via NMD or removal of DNA-binding zinc fingers

Variant classification. Pathogenic/likely pathogenic per ACMG/AMP; all variants **absent from gnomAD, RGC-ME, and All of Us**, supporting pathogenicity.

Somatic vs germline. All MRXS37 variants are **germline**. (Notably, ZFX overexpression is documented as a somatic event in multiple cancers—hepatocellular carcinoma, renal, glioma—but that is distinct from the germline disorder.)

Functional consequences. Truncating variants → loss of function. Missense variants → altered transcriptional output: *"DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity"* (PMID: 38325380).

Modifier genes. None specifically identified; X-inactivation skewing is the dominant modifier of expression in females.

Epigenetic information. ZFX itself **escapes X-inactivation** and binds GC-rich CpG-island promoters. Its own gene contains a 1.5-kb CpG island: *"a 1.5-kb CpG island encompasses multiple transcription initiation sites as well as the first and second exons. The 5' portion of the CpG island displays promoter activity"* (PMID: 8188262). No disease-specific methylation episignature has been reported.

Chromosomal abnormalities. MRXS37 is caused by point/small variants; no large structural rearrangements are characteristic. (CMA is not the primary diagnostic modality.)

Section 5: Environmental Information

Environmental factors: None. MRXS37 is a purely genetic monogenic disorder. **Lifestyle factors:** Not applicable. **Infectious agents:** Not applicable.

There are no known environmental, occupational, dietary, or infectious contributors to MRXS37.

Section 6: Mechanism / Pathophysiology

Core mechanism. ZFX is a **general transcription factor and master regulator of stem-cell self-renewal**. In embryonic and hematopoietic stem cells, ZFX directly activates shared self-renewal target genes: *"Zfx directly activated common target genes in ESC and HSC, as well as ESC-specific target genes including ESC self-renewal regulators Tbx3 and Tcl1"* (PMID: 17448993). Germline ZFX variants disrupt this transcriptional program during neurodevelopment.

Molecular pathway. ZFX has been linked to **canonical Wnt signaling** as a proposed mechanism for its self-renewal role: *"it appears that the ZFX is linked to the canonical Wnt signaling, which is one possible mechanism to explain the role of ZFX in the self-renewal of stem cells"* (PMID: 39712568). ZFX and ZFY are *"zinc-finger proteins that encode general transcription factors abundant in hematopoietic and embryonic stem cells"* (PMID: 39712568), with self-renewal regulation almost exclusive to ZFX.

Causal chain:

```
Germline ZFX variant (Xp22.11)
        │
        ├── Truncating → LoF (NMD / loss of DNA-binding zinc fingers)
        └── Missense (C-terminal ZFs) → altered DNA binding / transcription
        │
        ▼
Dysregulated transcription at GC-rich CpG-island promoters
(altered expression of self-renewal / developmental targets;
 canonical Wnt linkage)
        │
        ▼
Perturbed neural progenitor / stem-cell self-renewal & differentiation
        │
        ▼
Abnormal brain and craniofacial development
        │
        ▼
Developmental delay, intellectual disability, behavioral abnormalities,
recurrent facial gestalt, hypotonia
        │
        └── (missense subset) → parathyroid/tumor predisposition
            (hyperparathyroidism, tumor enrichment)
```

Cellular processes. Stem-cell/progenitor self-renewal (GO:0019827), regulation of transcription by RNA polymerase II (GO:0006357), cell proliferation and survival. ZFX's oncologic literature shows it controls proliferation, cell-cycle progression, and apoptosis resistance across tumor types.

Protein dysfunction. Missense variants impair sequence-specific DNA binding via the terminal C2H2 zinc fingers; truncating variants remove the DNA-binding module or trigger NMD. Both converge on transcriptional dysregulation.

Immune involvement / metabolic changes / tissue damage: Not primary features. There is no autoimmune, inflammatory, or classic metabolic-crisis component.

Molecular profiling. In vitro expression profiling of DNA-binding-domain variants demonstrated differential expression of a small set of ZFX target genes relative to wild-type—the direct functional readout of pathogenicity (PMID: 38325380).

Suggested ontology terms: GO:0019827 (stem cell population maintenance), GO:0006357 (regulation of transcription by RNA Pol II), GO:0060070 (canonical Wnt signaling pathway); CL:0000047 (neuronal stem cell), CL:0000034 (stem cell).

Section 7: Anatomical Structures Affected

Organ / system level: - **Primary:** Central nervous system / brain (UBERON:0000955) — nervous system (UBERON:0001016). Manifested as cognitive, behavioral, and tone abnormalities. - **Craniofacial structures:** face (UBERON:0000033), eyebrow, philtrum, external ear — reflected in the recurrent facial gestalt. - **Secondary/endocrine:** parathyroid gland (UBERON:0001132) in the missense subset with hyperparathyroidism.

Tissue / cell level: Nervous tissue; neural stem/progenitor cells (CL:0000047), broadly stem cells (CL:0000034). ZFX's normal role in hematopoietic and embryonic stem cells implies neural progenitor involvement during development.

Subcellular level: Nucleus (GO:0005634) — ZFX is a nuclear transcription factor acting at chromatin/promoters (GO:0005667, transcription regulator complex).

Localization / lateralization: The facial gestalt and neurodevelopmental features are **bilateral and symmetric**. No lateralized findings reported.

Section 8: Temporal Development

Onset. Congenital / early childhood. Developmental delay and the facial gestalt are recognizable from infancy; onset pattern is **chronic/insidious** (a developmental, not acute, presentation).

Progression. Static and non-progressive. MRXS37 is a stable developmental encephalopathy rather than a neurodegenerative process. Individuals have been reported up to age 34 without documented deterioration or reduced survival.

Disease course. Chronic and lifelong; disability is stable. No relapsing–remitting or episodic pattern.

Remission / critical periods. No spontaneous remission. The relevant window for intervention is the **early developmental period**, when early-intervention therapies (speech, occupational, physical, behavioral) can optimize functional outcomes.

Section 9: Inheritance and Population

Epidemiology. Ultra-rare. As of 2026, only 18 individuals from 16 families have been reported (PMID: 38325380); no formal prevalence or incidence has been established, and no follow-up cohorts have appeared.

Inheritance pattern. X-linked. In the founding cohort, transmission was consistent with X-linked inheritance—10 variants de novo, 8 maternally inherited from mildly affected or unaffected mothers.

Penetrance / expressivity. High penetrance in hemizygous males; **variable/reduced penetrance and expressivity in heterozygous females**, governed by X-inactivation skewing. Expressivity is variable overall (borderline to moderate ID).

Sex ratio. Male-predominant clinical severity; the cohort comprised 14 males and 4 females. Males are more severely affected.

Germline mosaicism / founder effects / consanguinity / carrier frequency: Not specifically documented; given ultra-rarity there are no established founder alleles, consanguinity associations, or carrier-frequency estimates. Carrier mothers with skewed X-inactivation may be asymptomatic.

Population demographics / geographic distribution. No ethnic or geographic predilection identified; cases were ascertained internationally through exome/genome sequencing and multi-center collaboration.

Section 10: Diagnostics

Genetic testing is the definitive diagnostic modality. Because MRXS37 has no specific biochemical marker, diagnosis rests on identifying a pathogenic germline ZFX variant.

Modality	Utility for MRXS37
Whole exome sequencing (WES)	Primary diagnostic tool; how the founding cohort was identified
Whole genome sequencing (WGS)	Effective alternative; also used in the cohort
NDD/XLID gene panels	Useful if ZFX is included (many panels may not yet contain it)
Single-gene ZFX testing	Confirmatory / cascade testing once a familial variant is known
Chromosomal microarray (CMA)	Low yield — variants are point/small, not CNVs
Karyotype / FISH	Not indicated

Clinical tests / biomarkers. No specific laboratory biomarker. **Serum calcium and parathyroid hormone (PTH)** should be checked given hyperparathyroidism risk in missense-variant carriers. Tumor surveillance is prudent given observed tumor enrichment. Brain MRI may be performed to evaluate developmental delay but shows no pathognomonic finding.

Clinical criteria / differential diagnosis. Diagnosis is molecular. Differential diagnoses include other syndromic XLID disorders with facial dysmorphism and behavioral features (e.g., ATR-X syndrome, DLG3-related XLID 90, MCT8/SLC16A2 deficiency, Simpson-Golabi-Behmel syndrome). The **recurrent facial gestalt** (broad medial eyebrows, smooth/long philtrum, ear anomalies) can prompt targeted ZFX evaluation.

Screening. No newborn or population screening exists. **Cascade genetic testing** of at-risk relatives and prenatal/preimplantation testing are options once a familial variant is identified.

Recommended approach: Trio exome or genome sequencing for a child with unexplained developmental delay/ID plus the characteristic facial gestalt; confirm segregation and X-inactivation status in the mother.

Section 11: Outcome / Prognosis

Survival and mortality. No reduced survival documented; individuals reported up to age 34. MRXS37 is **generally non-life-limiting**.

Morbidity and function. Lifelong intellectual disability (borderline to moderate) and behavioral challenges constitute the principal morbidity. Functional prognosis is **comparatively favorable** among syndromic NDDs—many individuals attend mainstream school with support and can work under supervision.

Complications. Endocrine (hyperparathyroidism) and neoplastic (tumor enrichment) complications occur predominantly in missense-variant carriers and warrant monitoring. Behavioral comorbidities (autism, ADHD, sleep disturbance) affect daily functioning.

Prognostic factors. Sex (males more severely affected) and **variant class**: missense variants in the DNA-binding domain carry the added hyperparathyroidism/tumor risk, whereas truncating (LoF) variants are associated with the neurodevelopmental phenotype without the same reported endocrine/tumor enrichment. X-inactivation skewing predicts female severity.

Quality-of-life measures: No formal QoL data available.

Section 12: Treatment

No disease-modifying or gene-targeted therapy exists. Management is **supportive and multidisciplinary**, tailored to the individual's manifestations.

Domain	Intervention	Suggested NCIT concept
Developmental	Early intervention; special education	Early Intervention (NCIT:C154751)
Rehabilitative	Physical, occupational, and speech therapy	Rehabilitation Therapy (NCIT:C15917)
Behavioral	Behavioral therapy; ADHD/autism management; sleep hygiene	Behavioral Therapy (NCIT:C15819)
Endocrine	Monitoring/treatment of hyperparathyroidism (missense carriers)	Supportive Care (NCIT:C15300)
Oncologic	Tumor surveillance given tumor enrichment	Cancer Surveillance
Genetic	Genetic counseling; cascade testing	Genetic Counseling (NCIT:C15681)

Pharmacotherapy. Symptomatic only—e.g., standard agents for ADHD, sleep, or seizures if present. No ZFX-specific pharmacogenomic guidance exists.

Advanced therapeutics / experimental. No gene therapy, RNA-based therapy, or targeted therapy is available or in trials. There are **no MRXS37/ZFX interventional clinical trials** registered.

Treatment strategy. Individualized, guided by phenotype: neurodevelopmental support universally; endocrine and tumor surveillance selectively for missense-variant carriers.

Section 13: Prevention

Primary prevention: Not possible for a spontaneous germline disorder. **Genetic counseling** is the cornerstone for at-risk families.

Secondary prevention: In families with a known variant, **prenatal diagnosis** and **preimplantation genetic testing (PGT)** allow informed reproductive decisions. **Cascade carrier testing** identifies at-risk female relatives.

Tertiary prevention: Surveillance for complications—**serum calcium/PTH monitoring** for hyperparathyroidism and **tumor surveillance** in missense-variant carriers—plus early developmental intervention to optimize functional outcomes.

Counseling. Genetic counseling should address X-linked recurrence risk (carrier mothers have 50% transmission risk per pregnancy; sons inheriting the variant are affected, daughters are carriers with variable/attenuated expression depending on X-inactivation), and the role of skewed X-inactivation in maternal phenotype.

Immunization / public health / environmental interventions: Not applicable.

Section 14: Other Species / Natural Disease

Taxonomy. No naturally occurring MRXS37-equivalent disease has been described in non-human species. ZFX orthologs are highly conserved across vertebrates.

Orthologous genes. Mouse *Zfx* (the ortholog most functionally studied); the Zfx/Zfy family is *"highly conserved in vertebrates."* Mouse Zfx gene structure, including its CpG-island promoter, was characterized by Luoh & Page (PMID: 8188262).

Natural disease / veterinary relevance. None reported (OMIA has no corresponding entry). No zoonotic or cross-species transmission relevance—MRXS37 is a heritable genetic disorder, not communicable.

Comparative biology. The evolutionary conservation of ZFX's stem-cell self-renewal function underlies the utility of model organisms for studying its biology.

Section 15: Model Organisms

Zebrafish (*Danio rerio*). A **zfx loss-of-function zebrafish model** was generated in the founding study and showed a neurobehavioral phenotype without gross morphologic abnormality: *"a zebrafish model of ZFX loss displayed an altered behavioral phenotype"* (PMID: 38325380)—specifically decreased anxiety and impaired habituation. This model recapitulates the behavioral dimension of MRXS37 and is the most directly disease-relevant model available.

Mouse (*Mus musculus*). Extensive *Zfx* knockdown/knockout work established ZFX's role in embryonic and hematopoietic stem-cell self-renewal (PMID: 17448993) and in Hedgehog-driven tumorigenesis (basal cell carcinoma, medulloblastoma; PMID: 25164012). These models illuminate mechanism but were not built specifically to model the neurodevelopmental syndrome.

Cellular / in vitro. Cultured cells expressing MRXS37 DNA-binding-domain variants demonstrated differential target-gene expression versus wild-type ZFX—the key functional assay establishing variant pathogenicity (PMID: 38325380). Human cancer cell lines (hepatocellular carcinoma, renal carcinoma, glioma) have been used to dissect ZFX's transcriptional targets (e.g., Nanog, SOX-2, Tbx3, Tcl1).

Model characteristics. The zebrafish model captures behavioral abnormality but not the facial gestalt or intellectual disability (which are difficult to model). No mouse model engineered with a specific human MRXS37 variant has yet been reported—a clear opportunity.

Resources. MGI (mouse *Zfx*), ZFIN (zebrafish *zfx*).

Mechanistic Model / Interpretation

MRXS37 is best understood as a **transcription-factor dosage/function disorder affecting stem-cell self-renewal programs during neurodevelopment**. ZFX normally sits at the top of a self-renewal transcriptional hierarchy, binding GC-rich CpG-island promoters and activating targets such as Tbx3 and Tcl1, with mechanistic links to canonical Wnt signaling. Germline perturbation of ZFX—whether by haploinsufficiency/LoF (truncating variants) or by altered DNA-binding activity (C-terminal missense variants)—dysregulates this program in neural progenitors and craniofacial precursors, producing the consistent developmental and dysmorphic phenotype.

The **genotype–phenotype split** is the most clinically actionable insight:

Feature	Truncating variants (LoF)	C-terminal missense variants
Count	7 variants	4 variants (11 subjects)
Mechanism	NMD / loss of DNA-binding zinc fingers	Altered transcriptional activity (gain or loss)
Neurodevelopmental phenotype	Yes	Yes
Hyperparathyroidism	Not reported	Yes (4 families)
Tumor enrichment	Not reported	Yes

This mirrors ZFX's dual identity in the literature: a **developmental self-renewal factor** (explaining the NDD) and a **somatic oncogene** overexpressed in hepatocellular, renal, glioma, and other cancers (explaining the tumor/endocrine enrichment in missense carriers). The missense variants may confer altered or partially gained transcriptional activity that tilts cells toward the proliferative/self-renewal state, plausibly connecting them to the neoplastic predisposition.

Sex and X-inactivation form the **second axis of variability**: males (hemizygous) fully express the phenotype, whereas heterozygous females' severity depends on which X is preferentially active—explaining mildly affected/unaffected carrier mothers and the male-predominant severity.

Evidence Base

PMID	Title (abbrev.)	Contribution
38325380	*Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt*	**Landmark defining study.** Cohort (18 subjects/16 families), variant spectrum, facial gestalt, hyperparathyroidism/tumor link, in vitro transcriptional assay, zebrafish model. The near-sole clinical source.
17448993	*Zfx controls the self-renewal of embryonic and hematopoietic stem cells*	Establishes ZFX's core function activating self-renewal targets (Tbx3, Tcl1). Mechanistic foundation.
39712568	*Maintenance of stem cell self-renewal by sex chromosomal zinc-finger transcription factors*	ZFX as general transcription factor; canonical Wnt linkage; ZFX (not ZFY) drives self-renewal.
8188262	*The structure of the Zfx gene on the mouse X chromosome*	Gene structure, CpG-island promoter—relevant to ZFX's GC-rich promoter binding.
25164012	*Zfx facilitates tumorigenesis caused by activation of the Hedgehog pathway*	Supports ZFX's oncogenic role (BCC, medulloblastoma), contextualizing tumor enrichment.
24585547, 27566731, 25441684, 22185393	ZFX in HCC, renal carcinoma, glioma	Corroborate ZFX's proliferation/self-renewal/anti-apoptotic function in somatic cancers via Nanog/SOX-2, CDK4/cyclin D1.

Evidence source types: The clinical phenotype and variant spectrum are **human clinical** (single cohort). The transcriptional-consequence data are **in vitro**. The behavioral phenotype is **model organism** (zebrafish). The self-renewal/oncogenic mechanism is **model organism** + **in vitro**.

Limitations and Knowledge Gaps

1. **Single-cohort evidence base.** Essentially all clinical knowledge derives from one 2024 study of 18 individuals. No independent replication, natural-history study, or registry exists. Phenotype frequencies are provisional.
2. **No prevalence/incidence data.** The disorder is too newly described and rare for epidemiologic estimation.
3. **Genotype–phenotype correlation is preliminary.** The missense→hyperparathyroidism/tumor association is based on only four families; causality and penetrance of the tumor risk are not established.
4. **Mechanism incompletely defined.** The precise ZFX target genes driving the neurodevelopmental phenotype, and whether missense variants act by gain vs. loss of function, remain unresolved ("gain or loss of transcriptional activity").
5. **No purpose-built mammalian disease model.** The zebrafish captures behavior only; no mouse carries a patient-specific ZFX variant.
6. **No therapeutics.** No disease-modifying treatment, trial, or biomarker for treatment response.
7. **Female phenotype poorly characterized.** X-inactivation's quantitative effect on severity in heterozygous females needs systematic study.

Proposed Follow-up Experiments / Actions

1. **Expand the cohort** via GeneMatcher/DECIPHER and international collaboration to refine phenotype frequencies, penetrance, expressivity, and the tumor/endocrine association; establish a patient registry.
2. **Longitudinal natural-history study** to define developmental trajectory, adult outcomes, and tumor/parathyroid surveillance intervals.
3. **Functional dissection of variant classes:** systematic transcriptomic (RNA-seq) and ChIP-seq comparison of truncating vs. missense variants in isogenic neural progenitors/iPSC-derived neurons to resolve gain- vs. loss-of-function and identify the neurodevelopmentally relevant target genes.

4. **Generate patient-specific mouse (or brain-organoid) models** carrying recurrent variants (e.g., p.Thr771Met, p.Arg786Gln) to recapitulate cognitive, craniofacial, and tumor phenotypes.
5. **Define an X-inactivation–severity relationship** in carrier females through quantitative XCI assays correlated with phenotype.
6. **Investigate the ZFX–Wnt axis** in neural progenitors as a potential therapeutic node.
7. **Develop clinical surveillance guidelines**, especially calcium/PTH monitoring and tumor surveillance for missense-variant carriers.
8. **Search for a DNA-methylation episignature** to aid VUS classification, given ZFX's role at CpG-island promoters.

Report compiled from an autonomous multi-iteration investigation. Primary evidence: Shepherdson et al., 2024 (PMID: 38325380), supplemented by ZFX functional-biology literature.
